Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts

Journal of Steroid Biochemistry and Molecular Biology

Volumn 115, Issue 3-5, 2009, Pages 126-136

  Locke, Jennifer A ^a   Nelson, Colleen C ^a,b   Adomat, Hans H ^a   Hendy, Stephen C ^a   Gleave, Martin E ^a   Guns, Emma S Tomlinson ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Androgen synthesis; Castration resistant prostate cancer; Progesterone

Indexed keywords

ANDROGEN; CORTICOSTEROID; CYTOCHROME P450 17; PROGESTERONE; STEROID 5ALPHA REDUCTASE 2;

ADRENAL GLAND; ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STAGING; CASTRATION; CELL STRAIN LNCAP; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HUMAN; MALE; MOUSE; NONHUMAN; PROGESTERONE METABOLISM; PROSTATE CANCER; STEROIDOGENESIS; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANIMALS; CASTRATION; CELL LINE, TUMOR; CINNAMATES; DISEASE PROGRESSION; DRUG COMBINATIONS; ENZYME INHIBITORS; FINASTERIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KETOCONAZOLE; MALE; MICE; MICE, NUDE; MIFEPRISTONE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; NITRILES; PROGESTERONE; PROSTATIC NEOPLASMS; STEROIDS; TOSYL COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 67349187469     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.03.011     Document Type: Article

References (65)

1. So A., Gleave M., Hurtado-Col A., and Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 23 (2005) 1-9
2. Daskivich T.J., and Oh W.K. Recent progress in hormonal therapy for advanced prostate cancer. Curr. Opin. Urol. 16 (2006) 173-178
3. Klotz L. Combined androgen blockade: an update. Urol. Clin. North Am. 33 (2006) 161-166 v-vi
4. Sharifi N., Dahut W.L., and Figg W.D. Secondary hormonal therapy for prostate cancer: what lies on the horizon?. BJU Int. 101 (2008) 271-274
5. Samson D.J., Seidenfeld J., Schmitt B., Hasselblad V., Albertsen P.C., Bennett C.L., Wilt T.J., and Aronson N. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 (2002) 361-376
6. Attard G., Reid A.H., Yap T.A., Raynaud F., Dowsett M., Settatree S., Barrett M., Parker C., Martins V., Folkerd E., Clark J., Cooper C.S., Kaye S.B., Dearnaley D., Lee G., and de Bono J.S. Phase I clinical trial of a selective inhibitor of CYP17, Abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26 (2008) 4563-4571
7. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., Knudsen B., Hess D.L., Nelson C.C., Matsumoto A.M., Bremner W.J., Gleave M.E., and Nelson P.S. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67 (2007) 5033-5041
8. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., and Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66 (2006) 2815-2825
9. Ettinger S.L., Sobel R., Whitmore T.G., Akbari M., Bradley D.R., Gleave M.E., and Nelson C.C. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 64 (2004) 2212-2221
10. Mohler J.L., Gregory C.W., Ford III O.H., Kim D., Weaver C.M., Petrusz P., Wilson E.M., and French F.S. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10 (2004) 440-448
11. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11 (2005) 4653-4657
12. Labrie F. Adrenal androgens and intracrinology. Semin. Reprod. Med. 22 (2004) 299-309
13. Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A., Ettinger S.L., Gleave M.E., and Nelson C.C. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68 (2008) 6407-6415
14. Dillard P.R., Lin M.F., and Khan S.A. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell. Endocrinol. 295 (2008) 115-120
15. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., True L.D., and Nelson P.S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68 (2008) 4447-4454
16. Harris K.A., Weinberg V., Bok R.A., Kakefuda M., and Small E.J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J. Urol. 168 (2002) 542-545
17. Lam J.S., Leppert J.T., Vemulapalli S.N., Shvarts O., and Belldegrun A.S. Secondary hormonal therapy for advanced prostate cancer. J. Urol. 175 (2006) 27-34
18. Rogers N.E., and Avram M.R. Medical treatments for male and female pattern hair loss. J. Am. Acad. Dermatol. 59 (2008) 547-66 quiz 567-568
19. Bartsch G., Rittmaster R.S., and Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J. Urol. 19 (2002) 413-425
20. Musquera M., Fleshner N.E., Finelli A., and Zlotta A.R. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Exp. Rev. Anticancer Ther. 8 (2008) 1073-1079
21. Thompson I.M., Pauler Ankerst D., Chi C., Goodman P.J., Tangen C.M., Lippman S.M., Lucia M.S., Parnes H.L., and Coltman Jr. C.A. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J. Clin. Oncol. 25 (2007) 3076-3081
22. Tindall D.J., and Rittmaster R.S. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J. Urol. 179 (2008) 1235-1242
23. Hsieh A.C., and Ryan C.J. Novel concepts in androgen receptor blockade. Cancer J. 14 (2008) 11-14
24. Thorpe J.F., Jain S., Marczylo T.H., Gescher A.J., Steward W.P., and Mellon J.K. A review of phase III clinical trials of prostate cancer chemoprevention. Ann. R. Coll. Surg. Engl. 89 (2007) 207-211
25. Auchus R.J., and Miller W.L. Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol. Endocrinol. 13 (1999) 1169-1182
26. Labrie F., Luu-The V., Lin S.X., Simard J., Labrie C., El-Alfy M., Pelletier G., and Belanger A. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 25 (2000) 1-16
27. Penning T.M., and Byrns M.C. Steroid hormone transforming aldo-keto reductases and cancer. Ann. N.Y. Acad. Sci. 1155 (2009) 33-42
28. Koh E., Noda T., Kanaya J., and Namiki M. Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 (2002) 154-159
29. Auchus R.J. The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab. 15 (2004) 432-438
30. Mathieu A.P., Auchus R.J., and LeHoux J.G. Comparison of the hamster and human adrenal P450c17 (17 alpha-hydroxylase/17,20-lyase) using site-directed mutagenesis and molecular modeling. J. Steroid Biochem. Mol. Biol. 80 (2002) 99-107
31. Ghayee H.K., and Auchus R.J. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev. Endocr Metab. Disord. 8 (2007) 289-300
32. Grigoryev D.N., Long B.J., Nnane I.P., Njar V.C., Liu Y., and Brodie A.M. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br. J. Cancer 81 (1999) 622-630
33. Stuart J.D., Lee F.W., Simpson Noel D., Kadwell S.H., Overton L.K., Hoffman C.R., Kost T.A., Tippin T.K., Yeager R.L., Batchelor K.W., and Bramson H.N. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat. Biochem. Pharmacol. 62 (2001) 933-942
34. Brozic P., Golob B., Gomboc N., Rizner T.L., and Gobec S. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3). Mol. Cell. Endocrinol. 248 (2006) 233-235
35. Lin M.F., Kawachi M.H., Stallcup M.R., Grunberg S.M., and Lin F.F. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26 (1995) 194-204
36. Vicentini C., Festuccia C., Angelucci A., Gravina G.L., Muzi P., Eleuterio E., Miano R., Marronaro A., Tubaro A., and Bologna M. Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. Anticancer Res. 22 (2002) 2917-2922
37. Huang W., Shostak Y., Tarr P., Sawyers C., and Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J. Biol. Chem. 274 (1999) 25756-25768
38. Grigoryev D.N., Long B.J., Njar V.C., and Brodie A.H. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J. Steroid Biochem. Mol. Biol. 75 (2000) 1-10
39. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y., Scheffler J.E., Salvati M.E., Krystek Jr. S.R., Weinmann R., and Einspahr H.M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4904-4909
40. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23 (2005) 8253-8261
41. Huang H., and Tindall D.J. The role of the androgen receptor in prostate cancer. Crit. Rev. Eukaryot. Gene Exp. 12 (2002) 193-207
42. Taplin M.E., Manola J., Oh W.K., Kantoff P.W., Bubley G.J., Smith M., Barb D., Mantzoros C., Gelmann E.P., and Balk S.P. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 101 (2008) 1084-1089
43. Small E.J., Baron A.D., Fippin L., and Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 157 (1997) 1204-1207
44. Labrie F., Dupont A., Cusan L., Manhes G., Bergeron N., Lacourciere Y., Pineault S., Belanger A., Monfette G., and Emond J. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer. Prog. Clin. Biol. Res. 303 (1989) 161-167
45. Mahler C., Verhelst J., and Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin. Pharmacokinet. 34 (1998) 405-417
46. Dawson N., Figg W.D., Brawley O.W., Bergan R., Cooper M.R., Senderowicz A., Headlee D., Steinberg S.M., Sutherland M., Patronas N., Sausville E., Linehan W.M., Reed E., and Sartor O. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin. Cancer Res. 4 (1998) 37-44
47. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., and Giovannucci E. Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 98 (2006) 1819-1825
48. Yap T.A., Carden C.P., Attard G., and de Bono J.S. Targeting CYP17: established and novel approaches in prostate cancer. Curr. Opin. Pharmacol. 8 (2008) 449-457
49. Handratta V.D., Vasaitis T.S., Njar V.C., Gediya L.K., Kataria R., Chopra P., Newman Jr. D., Farquhar R., Guo Z., Qiu Y., and Brodie A.M. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48 (2005) 2972-2984
50. Chen Y., Sawyers C.L., and Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 8 (2008) 440-448
51. Taplin M.E. Androgen receptor: role and novel therapeutic prospects in prostate cancer. Exp. Rev. Anticancer Ther. 8 (2008) 1495-1508
52. Beardsley E.K., and Chi K.N. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr. Opin. Support. Palliat. Care 2 (2008) 161-166
53. Zoubeidi A., Zardan A., Beraldi E., Fazli L., Sowery R., Rennie P., Nelson C., and Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 67 (2007) 10455-10465
54. Ryan C.J., Halabi S., Ou S.S., Vogelzang N.J., Kantoff P., and Small E.J. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin. Cancer Res. 13 (2007) 2030-2037
55. Madan R.A., and Arlen P.M. Abiraterone. Cougar biotechnology. IDrugs 9 (2006) 49-55
56. Gupta M.K., Guryev O.L., and Auchus R.J. 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. Arch. Biochem. Biophys. 418 (2003) 151-160
57. Ghayee H.K., and Auchus R.J. Clinical implications of androgen synthesis via 5alpha-reduced precursors. Endocr. Dev. 13 (2008) 55-66
58. Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., and Isaacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin. Cancer Res. 12 (2006) 4072-4079
59. Titus M.A., Gregory C.W., Ford 3rd O.H., Schell M.J., Maygarden S.J., and Mohler J.L. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11 (2005) 4365-4371
60. Wako K., Kawasaki T., Yamana K., Suzuki K., Jiang S., Umezu H., Nishiyama T., Takahashi K., Hamakubo T., Kodama T., and Naito M. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J. Clin. Pathol. 61 (2007) 448-454
61. Ryan C., Smith M., Rosenberg J., Lin A., Taplin M., Kantoff P., Huey V., Kim J., and Small E. Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC). J. Clin. Oncol. 26 (2008)
62. Arena F. Dutasteride in the treatment of hormone refractory prostate cancer. Minerva Urol. Nefrol. 60 (2008) 71-76
63. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab. 22 (2008) 331-340
64. Taplin M., Ko M., Regan M., Beer M., Carducci A., Bubley M., Oh K., Kantoff W., and Balk S. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J. Clin. Oncol. 26 (2008)
65. Petrylak D.P., Ankerst D.P., Jiang C.S., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., Burch P.A., Kohli M., Benson M.C., Small E.J., Raghavan D., and Crawford E.D. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 98 (2006) 516-521